254 related articles for article (PubMed ID: 23673317)
1. Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer.
Agnihotri N; Kumar S; Mehta K
Breast Cancer Res; 2013 Feb; 15(1):202. PubMed ID: 23673317
[TBL] [Abstract][Full Text] [Related]
2. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.
Kumar A; Xu J; Sung B; Kumar S; Yu D; Aggarwal BB; Mehta K
Breast Cancer Res; 2012 Jan; 14(1):R4. PubMed ID: 22225906
[TBL] [Abstract][Full Text] [Related]
3. PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.
Karicheva O; Rodriguez-Vargas JM; Wadier N; Martin-Hernandez K; Vauchelles R; Magroun N; Tissier A; Schreiber V; Dantzer F
Oncotarget; 2016 Sep; 7(39):64109-64123. PubMed ID: 27579892
[TBL] [Abstract][Full Text] [Related]
4. Transglutaminase 2 and NF-κB: an odd couple that shapes breast cancer phenotype.
Brown KD
Breast Cancer Res Treat; 2013 Jan; 137(2):329-36. PubMed ID: 23224146
[TBL] [Abstract][Full Text] [Related]
5. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
Agnihotri N; Mehta K
Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794
[TBL] [Abstract][Full Text] [Related]
6. Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways.
Kumar S; Donti TR; Agnihotri N; Mehta K
Int J Cancer; 2014 Jun; 134(12):2798-807. PubMed ID: 24477458
[TBL] [Abstract][Full Text] [Related]
7. Role of tissue transglutaminase 2 in the acquisition of a mesenchymal-like phenotype in highly invasive A431 tumor cells.
Lin CY; Tsai PH; Kandaswami CC; Chang GD; Cheng CH; Huang CJ; Lee PP; Hwang JJ; Lee MT
Mol Cancer; 2011 Jul; 10():87. PubMed ID: 21777419
[TBL] [Abstract][Full Text] [Related]
8. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer.
Mehta K; Kumar A; Kim HI
Biochem Pharmacol; 2010 Dec; 80(12):1921-9. PubMed ID: 20599779
[TBL] [Abstract][Full Text] [Related]
9. Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition.
Fisher ML; Adhikary G; Xu W; Kerr C; Keillor JW; Eckert RL
Oncotarget; 2015 Aug; 6(24):20525-39. PubMed ID: 25971211
[TBL] [Abstract][Full Text] [Related]
10. Tissue transglutaminase-mediated chemoresistance in cancer cells.
Verma A; Mehta K
Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
[TBL] [Abstract][Full Text] [Related]
11. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
[TBL] [Abstract][Full Text] [Related]
12. Tissue transglutaminase expression promotes castration-resistant phenotype and transcriptional repression of androgen receptor.
Han AL; Kumar S; Fok JY; Tyagi AK; Mehta K
Eur J Cancer; 2014 Jun; 50(9):1685-96. PubMed ID: 24656569
[TBL] [Abstract][Full Text] [Related]
13. Tissue transglutaminase induces Epithelial-Mesenchymal-Transition and the acquisition of stem cell like characteristics in colorectal cancer cells.
Ayinde O; Wang Z; Griffin M
Oncotarget; 2017 Mar; 8(12):20025-20041. PubMed ID: 28223538
[TBL] [Abstract][Full Text] [Related]
14. Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells.
Kumar A; Xu J; Brady S; Gao H; Yu D; Reuben J; Mehta K
PLoS One; 2010 Oct; 5(10):e13390. PubMed ID: 20967228
[TBL] [Abstract][Full Text] [Related]
15. Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer.
Cao L; Shao M; Schilder J; Guise T; Mohammad KS; Matei D
Oncogene; 2012 May; 31(20):2521-34. PubMed ID: 21963846
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of transglutaminase 2 (TG2) at serine-216 has a role in TG2 mediated activation of nuclear factor-kappa B and in the downregulation of PTEN.
Wang Y; Ande SR; Mishra S
BMC Cancer; 2012 Jul; 12():277. PubMed ID: 22759359
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer.
Mehta K; Fok J; Miller FR; Koul D; Sahin AA
Clin Cancer Res; 2004 Dec; 10(23):8068-76. PubMed ID: 15585642
[TBL] [Abstract][Full Text] [Related]
18. IL-1β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells.
Oh K; Lee OY; Park Y; Seo MW; Lee DS
BMC Cancer; 2016 Sep; 16(1):724. PubMed ID: 27609180
[TBL] [Abstract][Full Text] [Related]
19. Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer.
Yakubov B; Chelladurai B; Schmitt J; Emerson R; Turchi JJ; Matei D
Neoplasia; 2013 Jun; 15(6):609-19. PubMed ID: 23730209
[TBL] [Abstract][Full Text] [Related]
20. Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells.
Kumar A; Gao H; Xu J; Reuben J; Yu D; Mehta K
PLoS One; 2011; 6(6):e20701. PubMed ID: 21687668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
